The GigHz Briefing
When public markets look overvalued and returns flatten, where do disciplined investors turn? In this opening episode, Dr. Pouyan Golshani explains why the next decade of growth may belong to private, early-stage companies—where valuations have quietly reset 30 to 70 percent lower since 2021. From med-tech and AI to advanced materials like graphene, he explores how tighter capital has created rare entry points for accredited investors seeking true asymmetric upside. You’ll hear how Dr. Golshani applies the same precision he brings to interventional radiology to due-diligence, deal structure, and risk management—helping physicians and professionals access opportunities typically reserved for institutions. Key Themes: • Why high P/E public markets limit forward returns • How seed-stage valuations are creating generational entry points • Where innovation and intelligent capital now intersect • Why clarity and structure—not speculation—define real alpha 🎧 Hosted by Dr. Pouyan Golshani | Learn more at GigHz.com
3 episodios
Comentarios
0Sé la primera persona en comentar
¡Regístrate ahora y únete a la comunidad de The GigHz Briefing!